Loading company financials…
NASDAQ NMS - GLOBAL MARKET · Biotechnology · CIK 0001178670
$225.10
-2.43% · delayed ~15 min
Last price from Oct 21, 2026
$29.80B market value
From ALNYLAM PHARMACEUTICALS, INC.'s FY2025 10-K, filed Feb 12, 2026 · read the filing
ALNYLAM PHARMACEUTICALS develops and makes medicines. It took in $3.71B last year, which makes it a mid-sized company. Of every dollar it sells, about 8 cents is left as profit.
The financial picture is led by growth, with profitability and debt worth watching.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Recent open-market selling by SUPRAN BRYAN, not under a pre-arranged plan.
$398.9K sold in the last 120 days · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
Generally healthy, with a few things to watch.
From ALNYLAM PHARMACEUTICALS, INC.'s FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Revenue
$2.25B → $3.71B
Gross profit
$1.94B → $3.04B
Operating income
-$176.9M → $501.6M
Profit
-$278.2M → $313.7M
Measured against FY2024, from the 10-K filed Feb 12, 2026
Improved: +65.2%
$2.25B to $3.71BCritical
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
How the latest move compares (quote delayed ~15 min), and what was published around it
ALNY fell 2.43% on the latest quote. The average Health Care company tracked here moved +1.63%, and the S&P 500 −1.04%. That is 4.1 points below its sector and 1.4 points below the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 20% a year for the next 10 years. Over the last 2 years it grew by about 233% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 8 cents of every dollar of sales as profit, earning $313.7M last year.
Yes, quickly. Sales grew 65.2% last year.
It is tight. For every $1 it owes, it owns $1.19 in assets.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $313.7M and generated $524.1M of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 12, 2026Filing for FY2025 | FY202410-K · Feb 13, 2025Filing for FY2024 | FY202310-K · Feb 15, 2024Filing for FY2023 | FY202210-K · Feb 15, 2024Filing for FY2022 | FY202110-K · Feb 15, 2024Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $3.71B | $2.25B | $1.83B | $1.04B | $844.3M | +65.2% |
| Cost of revenue | $677.2M | $306.5M | $268.2M | $140.2M | $115.0M | +120.9% |
| Gross profit | $3.04B† | $1.94B† | $1.56B† | $897.2M† | $729.3M† | +56.4% |
| Gross marginGross profit ÷ revenueWhat is this? | 81.8% | 86.4% | 85.3% | 86.5% | 86.4% | −4.6 pts |
| Selling, general and administrative | $1.21B | $975.5M | $795.6M | $770.7M | $620.6M | +24.1% |
| Operating income | $501.6M | -$176.9M | -$282.2M | -$785.1M | -$708.7M | n/m |
| Operating marginOperating income ÷ revenueWhat is this? | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% | +21.4 pts |
| Interest expense | $252.6M | $141.9M | $121.2M | $156.0M | $143.0M | +78.1% |
| Income before tax | $323.2M | -$377.4M | -$433.5M | -$1.13B | -$852.1M | n/m |
| Net income | $313.7M | -$278.2M | -$440.2M | -$1.13B | -$852.8M | n/m |
| Net marginNet income ÷ revenueWhat is this? | 8.4% | -12.4% | -24.1% | -109.0% | -101.0% | +20.8 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $2.37 | $-2.15 | $-3.50 | $-9.13 | $-7.10 | n/m |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| ALNYALNYLAM PHARMACEUTICALS, INC. · this page | 7.3/10 | 5/8 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Sold on the open market — 1,758 shares at $226.88 ($398.9K)
Holds 12,807 shares after this filing.
Was granted or awarded shares — 107 shares
Holds 95,802 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Quarterly report for Q2 FY2026
Revenue +66.9% · Operating margin +20.0 pts · Gross profit +57.2% — against Q2 FY2025
Read the filingPublished results
Read the filingWrite down why you are following ALNYLAM PHARMACEUTICALS, INC., what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 23 subsidiaries named in its 10-K. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from ALNY's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 12, 2026), reported under the US GAAP taxonomy. View the source filing.
3 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. Accounting had too few reported figures and is left out of the average rather than counted as a weakness, so a company is never marked down for a figure it did not publish. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 8 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 6.0 | 5/8 | 10-K, filed Feb 12, 2026 |
| FY2024 | 4.7 | 4/8 | 10-K, filed Feb 13, 2025 |
| FY2023 | 4.7 | 5/8 | 10-K, filed Feb 15, 2024 |
| FY2022 | 4.7 | 3/8 | 10-K, filed Feb 23, 2023 |
| FY2021 | 4.7 | 4/8 | 10-K, filed Feb 10, 2022 |
| FY2020 | 4.7 | 3/8 | 10-K, filed Feb 11, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
5 of 8 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's. One could not be evaluated and is excluded from the total rather than counted as a failure.
4.10
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — This company has not reported enough of the required figures to calculate this score.
This company has not reported enough of the required figures to calculate this score.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +56.4%
$1.94B to $3.04BCritical
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: turned positive
-$176.9M to $501.6MCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: turned positive
-$278.2M to $313.7MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +21.4 pts
-7.9% to 13.5%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +20.8 pts
-12.4% to 8.4%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: turned positive
-$42.6M to $465.4MCritical
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Improved: turned positive
-$2.15 to $2.37Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +71.5%
$966.4M to $1.66BCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Changed: +71.2%
$34.3M to $58.7MCritical
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Deteriorated: −4.6 pts
86.4% to 81.8%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Deteriorated: +2.4%
129.3M to 132.4MNotable
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Jul 30, 2026 — read it.
Improved: +66.9%
$773.7M to $1.29BCritical
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +57.2%
$631.7M to $992.7MCritical
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: turned positive
-$16.2M to $231.4MCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: turned positive
-$72.2M to $164.5MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +20.0 pts
-2.1% to 17.9%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +22.1 pts
-9.3% to 12.7%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: turned positive
-$0.55 to $1.23Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +53.4%
$1.11B to $1.71BCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: −4.8 pts
81.6% to 76.9%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Deteriorated: +2.1%
131.0M to 133.7MNotable
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 18% and 23%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 38 analysts covering this company, as of . Their views, not this site's.
Of 38 analysts publishing on this company, 9 say strong buy, 20 say buy and 9 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 5.8% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 54.2x — a high multiple relative to the current trailing profit.
This company has not reported enough of the required figures to calculate this score.
| 65.2% |
| 8.4% |
| 94.97x |
| 5.29x |
| MRNAModerna, Inc. | 6.0/10 | 3/9 | -39.9% | -145.2% | — | 0.43x |
|---|
| BIIBBIOGEN INC. | 9.0/10 | 6/9 | 2.2% | 13.1% | 28.82x | 0.61x |
|---|
| INCYINCYTE CORP | 10.0/10 | 6/8 | 21.2% | 25.0% | 18.04x | 0.35x |
|---|
| Median of peers | 9.0/10 | — | 2.2% | 13.1% | 23.43x | 0.43x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Filed notice to sell 1,758 shares ($398.9K) on or after .
Shares originally obtained via Restricted Stock Vesting.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Had a director or senior officer leave or join · Held a shareholder vote
Quarterly report for Q2 FY2026
Read the filingPublished results
Read the filingProxy statement for a shareholder meeting
Read the filingHad a director or senior officer leave or join
Read the filingAnnual report for FY2025
Revenue +65.2% · Operating margin +21.4 pts · Gross profit +56.4% — against FY2024
Read the filingPublished results
Read the filingPublished results
Read the filingReported another event
Read the filingHad a director or senior officer leave or join
Read the filingQuarterly report for Q3 FY2025
Revenue +149.3% · Operating margin +44.8 pts · Gross profit +151.1% — against Q3 FY2024
Read the filingPublished results
Read the filingSigned a material agreement · Took on a direct financial obligation
Read the filingSigned a material agreement · Took on a direct financial obligation · Sold shares outside a public offering · Reported another event
Read the filingReported another event
Read the filingQuarterly report for Q2 FY2025
Revenue +17.3% · Operating margin −9.5 pts · Operating income turned negative — against Q2 FY2024
Read the filingPublished results
Read the filingHad a director or senior officer leave or join
Read the filingSource: Exhibit 21 of the 10-K filed 2026-02-12. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Yahoo ·
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?
Yahoo ·
Why Should You Think About Vertex Differently Now?
Yahoo ·
Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index?
Yahoo ·
Merck KgaA Is Paying More Than Double for This Gene-Silencing Biotech, Which Is Soaring 125%
Yahoo ·
Why Merck KGaA Is Paying a 130% Premium For This Gene-Silencing Tech
Yahoo ·
Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
Yahoo ·
What Is The Case For Waiting On Moderna Stock?
Yahoo ·
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth With RNAi Commercial Momentum
ChartMill ·
Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings
Yahoo ·
Next-gen RNAi drugmaker City prices $200M IPO
Yahoo ·
Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results
Yahoo ·
Primary sources and further research